Literature DB >> 18386838

Site-specific drug delivery to the middle-to-lower region of the small intestine reduces food-drug interactions that are responsible for low drug absorption in the fed state.

Fumié K Tanno1, Shinji Sakuma, Yoshie Masaoka, Makoto Kataoka, Toshio Kozaki, Ryosei Kamaguchi, Yutaka Ikeda, Hiroyasu Kokubo, Shinji Yamashita.   

Abstract

Food-drug interactions may reduce the bioavailability of drugs taken after meals (negative food effects). We designed enteric-coated tablets that start to disintegrate when they reach the middle-to-lower region of the small intestine, and examined whether they could reduce negative food effects in dogs. Tablets containing trientine as a model drug were coated with hypromellose acetate succinate (HPMCAS) with various values of succinoyl group content. The time lag of drug dissolution from these enteric-coated tablets in simulated intestinal fluid of pH 6.8 increased as the succinoyl group content was decreased. The AUC of trientine after oral administration of its aqueous solution to fed dogs was one-eighth of that in fasted dogs. The low drug absorption in fed dogs was improved when trientine was administered as enteric-coated tablets. The average ratio of AUC in the fed state to that in the fasted state increased with decreasing succinoyl group content of HPMCAS. Negative food effects completely disappeared after oral administration of tablets coated with HPMCAS having a succinoyl group content of 6.2% or less, which probably disintegrated in the middle-to-lower small intestine. Our results indicated that food-drug interactions were avoided by separating the main absorption site of drugs from that of food components.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386838     DOI: 10.1002/jps.21382

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Food-drug interactions.

Authors:  Rabia Bushra; Nousheen Aslam; Arshad Yar Khan
Journal:  Oman Med J       Date:  2011-03

2.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

3.  The steady state pharmacokinetics of trientine in Wilson disease patients.

Authors:  Jan Pfeiffenberger; Carlot Kruse; Peter Mutch; Andrew Harker; Karl Heinz Weiss
Journal:  Eur J Clin Pharmacol       Date:  2018-02-07       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.